Begin dosing patients with RMC-5552 monotherapy
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 2 Mar 2021
- Due
- 30 Jun 2021
- Delivered
- April 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The company expects to begin dosing patients with monotherapy in the first half of 2021”
What we found
Evidence strength A What the grades mean
A later 10-Q reports that the first patient in the RMC-5552-01 monotherapy study was dosed in April 2021, within the first-half 2021 window.
-
A Revolution Medicines, Inc. 10-Q filed 2021-08-11
“The RMC-5552-01 study is ongoing, with the first patient dosed in April 2021.” ✓ confirmed on the page
-
A Revolution Medicines, Inc. 10-Q filed 2021-11-10
“The RMC-5552-01 study is ongoing, with the first patient dosed in April 2021.” ✓ confirmed on the page
Checked 27 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Begin
- Deliverable
- First patient dosing with RMC-5552 monotherapy
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Revolution Medicines, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-RVMD-025003 · Corrections policy